$599

AZ’s Forxiga T1DM filed in EU

AstraZeneca recently announced the European Medicines Agency has accepted the Forxiga application for the treatment of T1DM. Of note, AZ filed with 52-week DEPICT-1 data but only 24-week data from DEPICT-2. FDA filing for Farxiga in T1DM remains projected for H2 ’18.

This content is for Read Less members only.
Register
Already a member? Log in here